Curasight to speed up clinical therapeutic strategy with new phase I/IIa trial to include total of five cancer indications
Curasight A/S, a clinical development company based in Copenhagen, Denmark, announces that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
About Trial
The trial will investigate Curasight’s theranostic (therapeutics/diagnostics) approach by testing the diagnostic platform uTRACE and the treatment platform uTREAT in brain cancer (Glioblastoma), neuroendocrine tumours (NET), head-and-neck cancer (HNSCC), non-small cell lung cancer (NSCLC), and pancreatic cancer. To strengthen the Company’s capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
We believe the theranostic approach using radiopharmaceuticals to both diagnose and treat certain types of cancer has the potential to provide important new solutions to clinicians and patients,” said Curasight’s CEO, Ulrich Krasilnikoff. “We have already achieved important results in most of the indications with our diagnostics platform uTRACE as well as positive preclinical results in brain and lung cancer using our therapeutic solution uTREAT. By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.” The trial of five cancer types in parallel takes advantage of our theranostic platform working across tumour types as uPAR is expressed in the majority of all solid cancers. This also increases the likelihood of entering into partnering with pharma companies.
The phase I/IIa basket trial is part of Curasight’s strategy to be a leader in the field of theranostics within radiopharmaceuticals and diagnostics, combining improved diagnosis with more targeted, gentler and efficient treatment of cancers.
• The new study is in addition to Curasight’s ongoing Phase II trial investigating uTRACE in prostate cancer as part of the partnership agreement with Curium Inc., where the first interim data is expected Q3 2024.
• Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation. Curasight is entitled to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.
Curasight has developed a novel and innovative Theranostics platform for improved cancer diagnosis and treatment. The combination of using targeted radionuclide therapy to treat cancer, and a non-invasive PET imaging for diagnosing and monitoring, is known as Theranostics (Therapy + Diagnostics = Theranostics). Curasight’s solution combines the technologies uTREAT (targeted radionuclide therapy) and uTRACE (based on non-invasive PET imaging), both of which target uPAR. By performing imaging, and using the same substance for treatment, it can be more precisely predicted where the therapy will go.
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE) and Radioligand Therapy (uTREAT) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (uPAR).
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!